Medical retina

20 – 24 February 2017, Rome, Italy

MONDAY, 20 FEBRUARY 2017
TREATMENT OF DR AND RVO
08:30 Pre-test and welcome session Patricia Udaondo, Spain
09:00 Baseline characteristics of DME predictive of visual acuity and intravitreal therapy response
09:30 The place of ranibizumab, aflibercept, and dexamethasone intravitreal implant in the treatment of DME
10:00 Management of DME demonstrated with case studies
10:30 COFFEE BREAK
11:00 – DME with taught hyaloid and/or ERM; indications for surgery?
– Mixing and matching PRP and anti-VEGF for PDR treatment
Anat Loewenstein, Israel
12:30 LUNCH
13:30 ME in DR or RVO and extensive peripheral non perfusion; Impact of anti-VEGF on retina perfusion Anat Loewenstein, Israel
14:30 ME in RVO: Is there anything (age, imaging aspects, results of trials) that should guide us to the choice of treatment, to the best frequency (monthly, T&E, PRN) of treatment, or when to combine and protocols of combinations therapies? Patricia Udaondo, Spain
15:15 COFFEE BREAK
15:45 Vitreoretinal interface in RVO and role of surgery Anat Loewenstein, Israel
16:15 – 16:45 Cases with RVO Patricia Udaondo, Spain Anat Loewenstein, Israel
TUESDAY, 21 FEBRUARY 2017
UVEITIS
09:00 Main entities of infectious uveitis: diagnosis and treatment Carlos Pavesio, UK
10:00 COFFEE BREAK
10:30 Main entities of non infectious uveitis diagnosis and treatment Marc DeSmet, Netherlands
11:15 Management of uveitis-related complications Elisabetta Miserocchi, Italy
11:45 Clinical cases Carlos Pavesio, UK Marc DeSmet, Netherlands Elisabetta Miserocchi, Italy
12:30 LUNCH
IMAGING IN DIAGNOSTIC UVEITIS
13.30 How to investigate a patient with posterior Uveitis Carlos Pavesio, UK
14.15 Imaging for ongoing uveitis management Marc DeSmet, Netherlands
15.00 COFFEE BREAK
15:30 Advanced imaging of the inflamed choriocapillaris and stromal choroid Marc DeSmet, Netherlands
16:15 – 17:00 Imaging for diagnostic dilemmas or masquerade syndromes Elisabetta Miserocchi, Italy
WEDNESDAY, 22 FEBRUARY 2017
OCT INTERPRETATIONS
09:00 The concept of normality of OCT and OCT-A examination of the retina and choroid
09:30 OCT: the physics of pathologic signals from the retinal stroma
10:00 OCT-A: the physics of pathologic signals from the retinal and choroidal vasculature
10:30 COFFEE BREAK
11:00 OCT-A: acquisition and interpretation pearls, pitfalls and artefacts
11:30 – OCT classification of drusen and macular atrophy
– OCT features in wAMD – OCT-A features of CNV
Giuseppe Querques, Italy
12:30 LUNCH
13:30 OCT & OCT-A integrated images for management of wAMD Giuseppe Querques, Italy
14:00 OCT & OCT-A integrated images for setting an avascular and vascular PED; and for RAP and PCV Francine Behar-Cohen, France
15:00 COFFEE BREAK
15:30 – 17:00 – OCT & OCT-A integrated images for management of MMD (Myopic Macular Degeneration)
– OCT & OCT-A integrated images for management of ME in DR and RVO
Alexandre Matet, France

Francine Behar-Cohen, France

THURSDAY, 23 FEBRUARY 2017
MULTIMODAL RETINAL IMAGE OF RETINAL DYSTROPHIES
09:00 Retinal and Choroidal vascular diseases:
– Type 2 Macular telangiectasia, case studies
– CSCR and differential diagnoses
Francine Behar-Cohen, France
10:00 Retinitis pigmentosa case studies
10:30 COFFEE BREAK
11:00 Best disease and adult onset foveomacular vitelliform dystrophy case studies Giuseppe Querques, Italy
11:30 Pattern dystrophy case studies
12:00 Other retinal dystrophies
12:30 LUNCH
NEOVASCULAR MACULOPATHIES
13:30 Management of RAP Srinivas Sadda, USA
14:00 Management of PCV
14:45 Management of DMM Maurizio Battaglia Parodi, Italy
15:30 COFFEE BREAK
16:00 Management of CNV complicating angioid streaks Maurizio Battaglia Parodi, Italy
16:30 – 17:00 Management of Mac Tel Srinivas Sadda, USA
FRIDAY, 24 FEBRUARY 2017
AMD
09:00 How to assess the progression of dry AMD Maurizio Battaglia Parodi, Italy
09:30 Therapeutic supplements for non-neovascular AMD
10:15 COFFEE BREAK
10:45 Defining the components of AMD: CNV, activity of neovascularization, fibrosis, area of geographic atrophy, edema and other stromal alterations Maurizio Battaglia Parodi, Italy
11:30 Prognostic parameters in anti-VEGF therapy for neovascular AMD Mariacristina Parravano, Italy
12:00 What we have learned from trials and real world data: the optimal regimen of treatment
12:30 True and false signs of reactivation of a CNV
13:00 – 13:30 Test, certificates and farewell